Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
A Call to Action of Rare Cancers Europe encourages policy makers to take greater action to ensure rare cancers are not overlooked from the policy agenda.
Available data now allows evidence-based treatment of cancer diagnosed during pregnancy and new therapies are improving many young patients’ survival prospects, but couples’ preferences and values must continue to guide medical teams even when hope is scarce
A survey reveals that physicians outside the field of oncology are insufficiently updated on the latest advances in cancer care, thus increasing the risk of providing misleading information and inadequate support to patients.
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
The ICF aims to support, financially and practically, activities that enhance cancer prevention, diagnosis, treatment and follow-up where they are most needed
At an ESMO Live Roundtable, a panel of experts discussed the benefits and risk of COVID-19 vaccination in patients with cancer, the practicalities of vaccinating those undergoing immunosuppressant treatment and the potential advantages and disadvantages of flexible dosing intervals.
However, researchers’ concerns about missing opportunities to publish their real-world evidence-based papers in high-ranked scientific journals are justified to some extent due to lack of ‘best practices’ from publishers and suitable peer reviewers for these study designs
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Despite some share the concern of having their career plans delayed or disrupted by the pandemic, the new challenges emerged in these unprecedented times represent a unique opportunity to grow-up as oncology professionals and get ready to a new scenario where team working, humanisation of care and virtual education will be more crucial than ever.
Despite alternative modes of administering anticancer medicines have reinforced the idea that at-home cancer care may be sometimes feasible as well as preferred by patients, there are concerns about costs of and accessibility to these new opportunities.
Dr Stefan Zimmermann, ESMO Perspectives Editor-in-Chief, explains the key aspects of a new scenario in oncology emerging from the COVID-19 pandemic.
Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
